Protocol Ledger

NCT03949855 · Phase II · RECRUITING

Belimumab With Rituximab for Primary Membranous Nephropathy

Interventional Phase II clinical trial protocol NCT03949855 sponsored by National Institute of Allergy and Infectious Diseases (NIAID) in Gastroenterology, Hepatology, and Renal, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-03-06 Enrollment: 58 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03949855
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03949855
Protocol FieldVerified Registry Value
NCT IdentifierNCT03949855
Consolidated Lead SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Therapeutic Condition CohortGastroenterology, Hepatology, and Renal
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment58 participants (ESTIMATED)
Registered Start Date2020-03-06
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Gastroenterology, Hepatology, and Renal Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI